Crinetics Pharmaceuticals Prepares for Upcoming Financial Update

Author: Logan Wright Updated: 04-11-2025 08:18 AM

Crinetics Pharmaceuticals Announces Upcoming Financial Results

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) is gearing up to share its financial results for the first quarter of 2025 on May 8, 2025, following the market's close. This announcement is a part of the company's continued commitment to transparency and stakeholder communication. In addition to the financial update, management will also host a conference call aimed at discussing the results and presenting a business update later that evening.

Details of the Conference Call

The conference call is scheduled for 4:30 p.m. ET. On this call, participants will have the opportunity to hear directly from the company's leadership about their financial performance and insights into future strategies and goals. Those interested in participating can dial in using the following numbers:

Dial-in Numbers

Domestic: 1-833-470-1428

International: 1-404-975-4839

Conference ID: CRNXQ1

Webcast Access

For those who prefer to participate online, a live webcast will also be available. The direct link to the webcast can be found on the Crinetics Pharmaceuticals website, where attendees are encouraged to join a few minutes ahead of time to ensure they are connected before the call begins. This webcast will also be archived for future access in the Investor Relations section of the company’s website, providing easy access for investors unable to attend the live discussion.

About Crinetics Pharmaceuticals

Founded with a mission to combat endocrine diseases and related tumors, Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on discovering and developing innovative therapies. The company has made significant strides with its lead candidate, paltusotine, recognized as the first investigational oral selective somatostatin receptor type 2 (SST2) nonpeptide agonist, aimed at treating acromegaly and carcinoid syndrome associated with neuroendocrine tumors.

In addition to paltusotine, Crinetics is advancing Atumelnant, which targets congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of Crinetics' drug candidates are small molecules that can be taken orally, developed through in-house discovery efforts. The company is continuously exploring new treatment options for various endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, and obesity, among others.

Investor Relations Contact

For inquiries regarding investments, Gayathri Diwakar is the Head of Investor Relations. She can be reached via email at gdiwakar@crinetics.com or by phone at (858) 345-6340.

Corporate Communications Contact

Natalie Badillo is the Head of Corporate Communications. Media inquiries can be directed to her email at nbadillo@crinetics.com or by calling (858) 345-6075.

Frequently Asked Questions

What does Crinetics Pharmaceuticals focus on?

Crinetics specializes in developing novel therapeutics for endocrine diseases and related tumors affecting patients.

When will Crinetics report their financial results?

The company is set to announce its first quarter 2025 financial results on May 8, 2025.

How can investors participate in the conference call?

Investors can join the call via provided domestic and international dial-in numbers or through a live webcast.

What is paltusotine?

Paltusotine is an investigational therapy developed by Crinetics, designed to treat conditions such as acromegaly and carcinoid syndrome.

Who can I contact for media inquiries?

Natalie Badillo, Head of Corporate Communications, can be contacted for media-related questions.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.